Granules Pharmaceuticals receives USFDA approval for Glycopyrrolate Oral Solution

20 Aug 2024

Granules Pharmaceuticals receives USFDA approval for Glycopyrrolate Oral Solution

Granules India announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Oral Solution 1mg/5mL filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company.

It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa Oral Solution, 1 mg/5 mL of Merz Pharmaceuticals, LLC.

Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients aged three to 16 years who have neurological conditions associated with problem drooling.

Top Blogs

blog-article-image-one

Share Market

Low Price Shares

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Nifty 50 Top 10 Stocks

0 mins read . Dec 18, 2024

blog-article-image-one

Share Market

Best Stocks in 2025

0 mins read . Dec 18, 2024

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions